Skip to main content

Table 4 MMRM and LOCF_ANCOVA analysis of three focus outcomes from duloxetine clinical trials.

From: The efficacy of duloxetine: A comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials

  Study 1 Study 2 Study 3 Study 4 Study 5 Study 6 Study 7 Study 8
Dose 60 mg QD 60 mg QD 60 mg BID 60 mg BID 20 mg BID 40 mg BID 20 mg BID 40 mg BID 40 mg BID 60 mg BID 40 mg BID 60 mg BID
  Δ p Δ p Δ p Δ p Δ p Δ p Δ p Δ p Δ p Δ p Δ p Δ p
HAMD 17 Total Score
MMRM 4.9 < .001 2.2 .024 3.1 .009 0.9 .415 1.4 .143 1.5 .116 2.4 .034 3.6 .002 2.2 .001 3.3 < .001 1.4 .045 1.6 .014
LOCF 3.8 < .001 1.7 .048 2.1 .066 0.4 .681 1.2 .222 1.5 .138 2.4 .022 3.1 .003 2.2 .007 3.0 < .001 0.9 .253 1.5 .054
HAMD 17 Maier Subscale
MMRM 2.8 < .001 1.6 .003 2.0 .005 0.7 .282 1.2 .037 1.4 .012 1.1 .068 1.7 .005 1.4 < .001 2.0 < .001 0.9 .022 1.2 .002
LOCF 2.3 < .001 1.4 .007 1.0 .030 0.6 .481 1.0 .058 1.3 .012 1.5 .028 1.8 .004 1.4 .001 1.9 < .001 0.7 .090 1.0 .014
VAS Overall Pain Severity
MMRM 5.9 .055 4.4 .135 NA NA 0.3 .931 1.2 .731 1.0 .771 7.4 .035 5.5 .085 6.3 .050 5.6 .044 1.3 .625
LOCF 6.9 .019 5.2 .037 NA NA 3.5 .573 3.5 .647 3.2 .710 7.1 .048 6.1 .063 5.6 .086 7.8 .014 5.5 .066
  1. NA = not assessed